Follow
Angelo Di Leo
Angelo Di Leo
Hospital of Prato
Verified email at uslcentro.toscana.it - Homepage
Title
Cited by
Cited by
Year
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 366 (9503), 2087-2106, 2005
61412005
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
42752013
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
22162015
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 379 (9814), 432-444, 2012
21892012
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition …
S Loi, N Sirtaine, F Piette, R Salgado, G Viale, F Van Eenoo, G Rouas, ...
J Clin Oncol 31 (7), 860-867, 2013
17362013
MONARCH 3: abemaciclib as initial therapy for advanced breast cancer
MP Goetz, M Toi, M Campone, J Sohn, S Paluch-Shimon, J Huober, ...
J clin oncol 35 (32), 3638-3646, 2017
14412017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
12242017
Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3
DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ...
Journal of Clinical Oncology 36 (24), 2465-2472, 2018
9322018
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ...
The Lancet Oncology 19 (1), 27-39, 2018
8872018
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, ...
J Clin Oncol 28 (30), 4594-4600, 2010
7682010
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, ...
J Clin Oncol 28 (30), 4594-4600, 2010
7682010
Tailoring adjuvant endocrine therapy for premenopausal breast cancer
PA Francis, O Pagani, GF Fleming, BA Walley, M Colleoni, I Láng, ...
New England Journal of Medicine 379 (2), 122-137, 2018
6112018
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer
A Di Leo, HL Gomez, Z Aziz, Z Zvirbule, J Bines, MC Arbushites, ...
Journal of Clinical Oncology 26 (34), 5544, 2008
5612008
Dissecting the heterogeneity of triple-negative breast cancer
O Metzger-Filho, A Tutt, E De Azambuja, KS Saini, G Viale, S Loi, ...
Journal of clinical oncology 30 (15), 1879-1887, 2012
5122012
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples
M Tanner, D Gancberg, A Di Leo, D Larsimont, G Rouas, MJ Piccart, ...
The American journal of pathology 157 (5), 1467-1472, 2000
4942000
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
S Johnston, M Martin, A Di Leo, SA Im, A Awada, T Forrester, M Frenzel, ...
NPJ breast cancer 5 (1), 5, 2019
4562019
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled …
V Galimberti, BF Cole, G Viale, P Veronesi, E Vicini, M Intra, G Mazzarol, ...
The Lancet Oncology 19 (10), 1385-1393, 2018
449*2018
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement
S Guiu, S Michiels, F André, J Cortes, C Denkert, A Di Leo, BT Hennessy, ...
Annals of oncology 23 (12), 2997-3006, 2012
4052012
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
S Loi, A Giobbie-Hurder, A Gombos, T Bachelot, R Hui, G Curigliano, ...
The Lancet Oncology 20 (3), 371-382, 2019
403*2019
1st International consensus guidelines for advanced breast cancer (ABC 1)
F Cardoso, A Costa, L Norton, D Cameron, T Cufer, L Fallowfield, ...
The Breast 21 (3), 242-252, 2012
4032012
The system can't perform the operation now. Try again later.
Articles 1–20